Again, you sit there spouting mass generalisations about holders wearing rose tinted glasses, but again, offer nothing in the way of facts. If you give us a well supported argument against either DEP or Vivagel, I for one will sit and listen, you wont hear me correcting grammar because whether you can punctuate or not, you might have come up with some points that I haven't thought of and that adds value to this forum. We don't pretend that facts are important, they ARE important, so please use them in a rational argument. If you can't, then I wouldn't bother posting.. unless of course you have another agenda like our mate Mukesh.
The only thing you've managed to come up with so far is about timings, now it's no secret all holders would like these timeframes to come in as much as possible, but it's also very clear that we know how long clinical trials take, we also know the percentage of clinical trials are successful. Where your arguments come completely unstuck is your lack of knowledge around SPL and clearly missing the near guarantee of Vivagel to hit the market and how that significantly derisks the DEP platform.
SPL Price at posting:
64.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)